MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/alz.71746

Медицинская библиотека · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026

Long-term safety and immunogenicity of ABvac40 active immunotherapy in mild cognitive impairment and very mild Alzheimer's disease: Results from AB1601 phase 2 extension study.

Pascual-Lucas María, Lacosta Ana María, Montañés María, Canudas Jesús, Loscos Jorge, Monleón Inmaculada, Allué José Antonio, Sarasa Leticia, Fandos Noelia, Romero Judith, Sarasa Manuel, Torres Mireia, Whyms Dermot, Terencio Jose, Piñol-Ripoll Gerard, Boada Mercè

СтатьяКлиническое исследование II фазыРандомизированное исследованиеМногоцентровое исследованиеПеревод в очереди

Аннотация

INTRODUCTION

ABvac40 is an active immunotherapy targeting Aβ40, the main component of cerebrovascular deposition in Alzheimer's disease (AD). A 24-month randomized, placebo-controlled phase 2 study (Part A) showed favorable safety and robust immunogenicity, with exploratory signals of clinical efficacy. Here, we report results from Part B, an 18-month extension evaluating long-term safety and immunological memory.

METHODS

Participants treated with ABvac40 in Part A received placebo plus a delayed booster, whereas previous placebo participants received ABvac40. Exploratory endpoints included safety, tolerability, and immunogenicity.

RESULTS

Seventy-seven participants entered Part B. Treatment-emergent adverse events (TEAEs) occurred in 75.0% of participants in placebo + booster group and 81.1% in ABvac40 group; serious TEAEs were 5.0% and 16.2%, respectively. No ARIA-E or meningoencephalomyelitis were observed, with one ARIA-H event. ABvac40 induced robust antibody responses following delayed booster, with detectable anti-Aβ40 antibodies in CSF.

DISCUSSION: ABvac40 showed favorable long-term safety and durable immunogenicity, supporting further clinical development.

TRIAL REGISTRATION: ClinicalTrials.gov: NCT03461276, registered March 2, 2018. EudraCT: 2016-004352-30, registered March 10, 2017.

Для цитирования: Pascual-Lucas María, Lacosta Ana María, Montañés María, Canudas Jesús, Loscos Jorge, Monleón Inmaculada, Allué José Antonio, Sarasa Leticia, Fandos Noelia, Romero Judith, Sarasa Manuel, Torres Mireia, Whyms Dermot, Terencio Jose, Piñol-Ripoll Gerard, Boada Mercè. Long-term safety and immunogenicity of ABvac40 active immunotherapy in mild cognitive impairment and very mild Alzheimer's disease: Results from AB1601 phase 2 extension study.. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026. DOI: 10.1002/alz.71746.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.